Nasdaq:CRDF
Cardiff Oncology, Inc.
A clinical-stage biopharma firm developing targeted oncology therapies while managing significant operating losses and minimal current revenue.
Key Metrics
Investment Thesis
Bull Case
Investors may view CRDF as a high-risk, high-reward opportunity if the company's novel oncology assets achieve pivotal trial success and command substantial licensing deals. The current low revenue base ($0.6M) combined with a manageable balance sheet relative to typical biotech burn rates suggests there is still runway available for strategic pivots or asset sales. Successful data generation could re-rate the stock from a speculative clinical-stage valuation to a more established asset-heavy profile.
Bear Case
The stock faces severe downside risk due to an unsustainable cash burn rate of nearly $46M annually with negligible revenue streams and no significant operating income. The retained earnings deficit has deepened to -$430M, indicating that the company is entirely dependent on equity financing which will likely lead to repeated dilution of existing shareholders. With cash reserves declining and no clear path to profitability in the near term, the company may face insolvency or forced restructuring if clinical milestones are not met quickly.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc. (CRDF) is a clinical-stage biopharmaceutical company focused on developing novel therapies for oncology patients. The company serves the global cancer treatment market with a portfolio of proprietary small molecules targeting specific genetic mutations. Key products are currently in preclinical or early clinical development stages as the firm navigates a cash-burn-intensive R&D phase.
Analysis
Management Discussion
The company reported a net loss of $45.9M for the latest period, consistent with a widening deficit trend from -$38.7M in 2022 to -$45.9M recently. Operating expenses surged to $49.6M while revenue remained stagnant at roughly $0.6M, indicating that current burn is not covered by operational income. Cash flow from operations was negative $37.9M, with a net change in cash of -$34.0M, suggesting the company must secure significant external financing to continue its development programs.
Industry Overview
The global oncology sector is currently characterized by intense competition from large pharmaceutical companies and a shift towards targeted therapies based on genetic markers. However, early-stage biotech firms face a crowded landscape where only those with breakthrough science and efficient development models can survive the long R&D cycle. Regulatory scrutiny remains high, and investors are increasingly demanding evidence of commercial potential before committing significant capital.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $386.0K | $488.0K | $683.0K | $593.0K |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $386.0K | $488.0K | $683.0K | $593.0K |
| Operating Expenses | $40.3M | $45.9M | $49.3M | $49.6M |
| Operating Income | $-39.9M | $-45.4M | $-48.7M | $-49.0M |
| R&D | $27.1M | — | — | — |
| G&A | $13.2M | $13.0M | $12.5M | $14.2M |
| Stock-Based Comp | $4.3M | $4.5M | $4.8M | $5.7M |
| D&A | $236.0K | $398.0K | $404.0K | $364.0K |
| Depreciation | $200.0K | $400.0K | $400.0K | $400.0K |
| Other OpEx | $7.0K | $32.9M | $36.9M | $35.3M |
| Non-Operating Income | $0 | $0 | $0 | $3.1M |
| Interest Income | $1.6M | $4.1M | $3.3M | $3.1M |
| Pre-Tax Income | $-39.9M | $-45.4M | $-48.7M | $-45.9M |
| Income Tax | $0 | $0 | $0 | $0 |
| Continuing Ops | $-39.9M | $-45.4M | $-48.7M | $-45.9M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-38.7M | $-41.4M | $-45.4M | $-45.9M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-38.7M | $-41.4M | $-45.4M | $-45.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $111.3M | $77.4M | $95.1M | $60.1M |
| Cash & Equivalents | $16.3M | $21.7M | $51.5M | $17.5M |
| Marketable Securities | $88.9M | $53.2M | $40.3M | $40.8M |
| Accounts Receivable | $771.0K | $288.0K | $773.0K | $182.0K |
| Prepaid Expenses | $5.2M | $2.3M | — | — |
| Other Current Assets | $0 | $0 | $2.5M | $1.6M |
| Long-Term Assets | $4.9M | $4.2M | $2.1M | $1.8M |
| PP&E (Net) | $1.3M | $1.2M | $898.0K | $578.0K |
| Operating Leases | $2.3M | $1.7M | $1.2M | $629.0K |
| Other LT Assets | $1.4M | $1.3M | $69.0K | $549.0K |
| Total Assets | $116.2M | $81.6M | $97.2M | $61.9M |
| Current Liabilities | $7.8M | $10.4M | $13.4M | $16.4M |
| Accounts Payable | $2.0M | $2.0M | $4.8M | $8.1M |
| Current Leases | $675.0K | $691.0K | $710.0K | $730.0K |
| Other Current Liab | $0 | $0 | $0 | $0 |
| Long-Term Liabilities | $2.0M | $1.5M | $813.0K | $102.0K |
| LT Operating Leases | $2.0M | $1.5M | $813.0K | $102.0K |
| Other LT Liab | $0 | $0 | $0 | $0 |
| Total Liabilities | $9.8M | $11.9M | $14.2M | $16.5M |
| Shareholders' Equity | $106.3M | $69.7M | $82.9M | $45.4M |
| Paid-In Capital | $404.8M | $409.3M | $467.1M | $475.4M |
| Retained Earnings | $-298.1M | $-339.5M | $-384.2M | $-430.0M |
| AOCI | $-395.0K | $-67.0K | $34.0K | $50.0K |
| Total L&E | $116.2M | $81.6M | $97.2M | $61.9M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-38.7M | $-41.4M | $-45.4M | $-45.9M |
| Non-Cash Adjustments | $2.2M | $12.0M | $5.7M | $7.1M |
| Working Capital Changes | $2.7M | $-1.5M | $2.1M | $843.0K |
| Cash from Operations | $-33.8M | $-30.9M | $-37.7M | $-37.9M |
| Capital Expenditures | $1.0M | $582.0K | $80.0K | $44.0K |
| Cash from Investing | $38.1M | $36.2M | $13.7M | $1.3M |
| Cash from Financing | $75.0K | $0 | $53.8M | $2.6M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $4.4M | $5.3M | $29.8M | $-34.0M |
| Beginning Cash | $11.9M | $16.3M | $21.7M | $51.5M |
| Ending Cash | $16.3M | $21.7M | $51.5M | $17.5M |
Frequently Asked Questions
How does Cardiff Oncology, Inc. make money?
Oncology Drug Development, Preclinical Research Services, and Potential Future Licensing Agreements
What are the main risks for CRDF?
Significant cash burn rate of $37.9M with limited current revenue ($0.6M) creating high dilution risk, dependence on successful Phase 1/2 trial results for future valuation, limited operating liquidity with only $17.5M in cash and equivalents, and the inherent regulatory and commercial risks associated with early-stage biotechnology development.
What is CRDF's competitive advantage?
Proprietary small molecule platforms targeting unmet needs in specific cancer subtypes, a focus on reducing the size of clinical trials to accelerate time-to-market, and potential strategic partnerships to offset R&D costs.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.